Six-year outcomes in neovascular age-related macular degeneration with ranibizumab

作     者：Julie Jacob Heidi Brié Anita Leys Laurent Levecq Filip Mevgaerts Kris Denhaerynck Stefaan Vancayzeele Eline Van Craeyveld Ivo Abraham Karen MacDonald 

作者机构：Leuven University Eye HospitalKapucijnenvoer 33Leuven B-3000Belgium Novartis PharmaMedialaan 40Vilvoorde B-1800Belgium Catholic University of LouvainCHU UCL NamurYvoirB-5530Belgium Medisch Centrum AarschotLangdorpsesteenweg 129Aarschot B-3200Belgium Matrix456159 W Sunset RdTucsonAZ 85743USA Center for Health Outcomes and Pharmacoeconomic ResearchUniversity of ArizonaTucsonAZ 85721USA 

出 版 物：《International Journal of Ophthalmology(English edition)》 (国际眼科杂志（英文版）)

年 卷 期：2017年第10卷第1期

页      面：81-90页

核心收录：

学科分类：1002[医学-临床医学] 100212[医学-眼科学] 10[医学] 

基　　金：sponsored by Novartis Pharma 

主　　题：ranibizumab age-related macular degeneration visual acuity central retinal thickness optical coherence tomography visual function, long-term outcome 

摘      要：AIM： To evaluate the outcomes of （6y ranibizumab therapy in neovascular age-related macular degeneration （AMD）.METHODS： HELIX was a retrospective, observational effectiveness study using medical records of patients treated in three clinics in Belgium. Patients had neovascular AMD and were initially treated with intravitreal ranibizumab （0.5 mg） between November 1, 2007 and October 31, 2008, had （6y of data available, and were treated on an ongoing, as-needed basis. Outcomes included best-corrected visual acuity （BCVA） and central retinal thickness （CRT）.RESULTS： The sample consisted of 88 eyes from 69 patients. Mean age was 76.4±6.5y, most patients were female （62.3%）. Most eyes （62.5%） were treatment-naive, 33 previously treated eyes had received predominantly other anti-vascular endothelial growth factor agents and verteporfin. Mean baseline BCVA was 57.4±12.7 ETDRS letters and CRT was 291.5±86.1 （m. On average, patients received 20.6±11.9 ranibizumab injections over the （6y. Intervals between injections were on average 12.7±16.1wk. Mean change in BCVA from baseline to last observation for the sample was less than one letter （-0.9±17.3 letters）, with an average loss of -3.2±15.6 letters in previously treated eyes versus a gain of 0.6±18.4 letters in treatment-na？ve eyes. When considering a loss of 〈15 letters over 6y as stabilization of disease, 75.9% of all eyes showed a positive （improvement or stabilization） outcome. Mean change in CRT from baseline to last observation for the sample was -26.9±148.4 （m with the greatest reduction observed in treatment-naive ***： This retrospective study of 69 neovascular AMD patients treated for （6y with ranibizumab demonstrates long-term visual stabilization. In light of the natural evolution of the disease, these data confirm that ranibizumab is effective long-term under real-world conditions of heterogeneity of patients, clinicians, and centers.